SCHEMBL5875901

SCHEMBL5875901

Cc1ccc(S(=O)(=O)n2nc(Nc3ccccc3)c3c2CC(c2ccccc2)(c2ccc(N(C)C)cc2)C=C3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.39
ALDH1A1 P00352 6/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CNR2 P34972 1/20 0.35
LMNA P02545 2/20 0.34
MAPK1 P28482 2/20 0.34
GFER P55789 1/20 0.34
MCL1 Q07820 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
KDM1A O60341 1/20 0.34
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
CYP2C19 P33261 2/20 0.32
GAA P10253 3/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TP53 P04637 1/20 0.32
PPARG P37231 1/20 0.31
RAB9A P51151 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5878272 0.99 MAPT (0.39) MAPTALDH1A1SMN1; SMN2CNR2LMNA
SCHEMBL5875996 0.93 NR1H2 (0.38) MAPTALDH1A1SMN1; SMN2LMNAGFER
SCHEMBL5876345 0.93 MAPT (0.33) MAPTALDH1A1SMN1; SMN2LMNANR1H2
SCHEMBL5877311 0.92 MAPT (0.34) MAPTALDH1A1SMN1; SMN2CNR2LMNA
SCHEMBL5876873 0.90 ALDH1A1 (0.36) MAPTALDH1A1SMN1; SMN2LMNANR1H2
SCHEMBL5877764 0.89 NR1H2 (0.35) MAPTALDH1A1SMN1; SMN2LMNANR1H2
SCHEMBL5877164 0.89 ALDH1A1 (0.37) MAPTALDH1A1SMN1; SMN2LMNANR1H2
SCHEMBL5876491 0.88 ALDH1A1 (0.39) MAPTALDH1A1SMN1; SMN2CNR2LMNA
SCHEMBL5875821 0.88 KMT2A (0.40) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL5876253 0.88 NR1H2 (0.35) MAPTALDH1A1SMN1; SMN2LMNANR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT MAPT 1879/4885ALDH1A1 166/4885SMN1; SMN2 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.